These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 28143711)
1. Response to Pembrolizumab in a Patient With Chemotherapy Refractory Bladder Cancer With Small Cell Variant Histology: A Case Report and Review of the Literature. Wilde L; Ali SM; Solomides CC; Ross JS; Trabulsi E; Hoffman-Censits J Clin Genitourin Cancer; 2017 Jun; 15(3):e521-e524. PubMed ID: 28143711 [No Abstract] [Full Text] [Related]
2. Primary metastatic neuroendocrine small cell bladder cancer: a case report and literature review. Cerulli C; Busetto GM; Antonini G; Giovannone R; Di Placido M; Soda G; De Berardinis E; Gentile V Urol Int; 2012; 88(3):365-9. PubMed ID: 22236613 [TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab for the treatment of bladder cancer. Sundahl N; Rottey S; De Maeseneer D; Ost P Expert Rev Anticancer Ther; 2018 Feb; 18(2):107-114. PubMed ID: 29284318 [TBL] [Abstract][Full Text] [Related]
4. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. Wang VE; Urisman A; Albacker L; Ali S; Miller V; Aggarwal R; Jablons D J Immunother Cancer; 2017 Sep; 5(1):75. PubMed ID: 28923100 [TBL] [Abstract][Full Text] [Related]
5. [A Case of Successful Treatment of Small Cell Carcinoma of the Bladder with Pembrolizumab]. Aigase T; Tatenuma T; Uemura K; Makiyama K; Kobayashi N; Kato I; Yamanaka S; Fujii S Hinyokika Kiyo; 2024 Apr; 70(4):93-99. PubMed ID: 38965908 [TBL] [Abstract][Full Text] [Related]
6. A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder. Kao C; McNamara M; Alley C; Spector N; Jauhari S; Gupta RT; Zhang T; Zhu J Clin Genitourin Cancer; 2019 Jun; 17(3):e672-e677. PubMed ID: 31097390 [No Abstract] [Full Text] [Related]
7. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Frumovitz M; Westin SN; Salvo G; Zarifa A; Xu M; Yap TA; Rodon AJ; Karp DD; Abonofal A; Jazaeri AA; Naing A Gynecol Oncol; 2020 Sep; 158(3):570-575. PubMed ID: 32534809 [TBL] [Abstract][Full Text] [Related]
8. Urachal mixed adenocarcinoma and small cell neuroendocrine carcinoma with widespread metastasis and resistance to chemotherapy: a case report. Obiedat S; Murshed K; Szabados L; Al Rumaihi K; Al Bozom I Diagn Pathol; 2024 Jun; 19(1):81. PubMed ID: 38877561 [TBL] [Abstract][Full Text] [Related]
9. Advanced Bladder Cancer Rechallenged With an Immune Checkpoint Inhibitor: A Case Report. Bat T; Buck DA; Nathan R; Cinquino J; Sikorski M; Elefante A; Herbst L; Sule N; Fabiano A; George S Urology; 2019 Sep; 131():24-26. PubMed ID: 31059726 [No Abstract] [Full Text] [Related]
10. Three more immune checkpoint inhibitors for advanced bladder cancer. Med Lett Drugs Ther; 2017 Dec; 59(1535):e202-e203. PubMed ID: 29186087 [No Abstract] [Full Text] [Related]
11. NICE's rejection of pembrolizumab for platinum-refractory urothelial carcinoma: is there a greater good? Gupta S; Kamat AM Nat Rev Urol; 2020 Sep; 17(9):491-492. PubMed ID: 32632305 [TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab Treatment and Pathologic Therapeutic Evaluation for Granulocyte Colony-stimulating Factor-producing Bladder Cancer: A Case Report and Literature Review. Muramatsu-Maekawa Y; Taniguchi T; Ito H; Nakane K; Kato T; Tsuchiya T; Miyazaki T; Koie T; Mizutani K J Immunother; 2020 May; 43(4):134-138. PubMed ID: 32080020 [TBL] [Abstract][Full Text] [Related]
13. [Clinical and pathologic characteristics of small cell neuroendocrine carcinoma of urinary tract]. Guo AT; Chen W; Wei LX Zhonghua Bing Li Xue Za Zhi; 2012 Nov; 41(11):747-51. PubMed ID: 23302335 [TBL] [Abstract][Full Text] [Related]
14. [Small cell neuroendocrine carcinoma of the urinary bladder: a case report]. Iwamura H; Horii Y; Arai E Hinyokika Kiyo; 1999 Sep; 45(9):641-4. PubMed ID: 10540713 [TBL] [Abstract][Full Text] [Related]
15. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment. Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403 [TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab for Refractory Metastatic Myxofibrosarcoma: A Case Report. Song HN; Kang MG; Park JR; Hwang JY; Kang JH; Lee WS; Lee GW Cancer Res Treat; 2018 Oct; 50(4):1458-1461. PubMed ID: 29361819 [TBL] [Abstract][Full Text] [Related]
17. [New approval: Avelumab - maintenance therapy for advanced or metastatic urothelial carcinoma]. Le Brun IC; Benderra MA Bull Cancer; 2021 Sep; 108(9):784-786. PubMed ID: 34332742 [No Abstract] [Full Text] [Related]
18. [Small cell neuroendocrine carcinoma of the bladder: A case report and review of the literature]. Chekrine T; De Bari B; Cassier P; Kulisa M; Chapet O; Mornex F Cancer Radiother; 2011 Jun; 15(3):250-3. PubMed ID: 21420344 [TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet? Rammohan A; Reddy MS; Farouk M; Vargese J; Rela M Hepatology; 2018 Mar; 67(3):1166-1168. PubMed ID: 29023959 [No Abstract] [Full Text] [Related]
20. Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer. Garje R; Chau JJ; Chung J; Wanat K; Zakharia Y J Immunother; 2018 Jan; 41(1):42-44. PubMed ID: 29111983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]